Groth K E, McCullough J, Marker S C, Howard R J, Simmons R L, Najarian J S, Balfour H H
JAMA. 1978 May 5;239(18):1877-9.
Zoster immune plasma (ZIP) was evaluated for treatment of cutaneous disseminated zoster in immunocompromised hosts. Twenty patients were studied: 13 were enrolled in a double-blind protocol, five received ZIP under an open protocol, and two were observed without receiving a transfusion. In the double-blind study, eight patients actually received ZIP; five were given plasma lacking varicella-zoster virus antibodies (control plasma). The clinical course of zoster in the group given ZIP was the same as that of patients given control plasma or no transfusions. Because ZIP did not alter the clinical course of zoster and because zoster patients produced high-antibody titers without ZIP, we concluded that ZIP is not useful for treatment of cutaneous disseminated zoster and should be reserved for prevention or modification of varicella in exposed, susceptible immunocompromised patients.
对带状疱疹免疫血浆（ZIP）治疗免疫功能低下宿主的皮肤播散性带状疱疹进行了评估。研究了20例患者：13例纳入双盲方案，5例在开放方案下接受ZIP治疗，2例未接受输血观察。在双盲研究中，8例患者实际接受了ZIP治疗；5例给予缺乏水痘-带状疱疹病毒抗体的血浆（对照血浆）。接受ZIP治疗组的带状疱疹临床病程与接受对照血浆或未输血患者的相同。由于ZIP未改变带状疱疹的临床病程，且带状疱疹患者在未使用ZIP的情况下也产生了高抗体滴度，我们得出结论，ZIP对皮肤播散性带状疱疹的治疗无用，应保留用于暴露的、易感染的免疫功能低下患者预防或改变水痘。
